Advanced search
Publication Cover
mAbs Volume 11, 2019 - Issue 4
Submit an article Journal homepage
16,763
Views
59
CrossRef citations to date
0
Altmetric
Report

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

Nathan D. TrinkleinTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Duy PhamTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Ute SchellenbergerTeneobio, Inc., Menlo Park, CA, USAORCID Iconhttps://orcid.org/0000-0002-4809-9383View further author information
ORCID Icon,
Ben BuelowTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Andrew BoudreauTeneobio, Inc., Menlo Park, CA, USAORCID Iconhttps://orcid.org/0000-0002-0016-4561View further author information
ORCID Icon,
Priya ChoudhryDepartment of Laboratory Medicine, University of California, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-4438-1576View further author information
ORCID Icon,
Starlynn C. ClarkeTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Kevin DangTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Katherine E. HarrisTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Suhasini IyerTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Brett JorgensenTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Payal P. PratapTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Udaya S. RangaswamyTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Harshad S. UgamrajTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Omid VafaTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Arun P. WiitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-7465-6964View further author information
ORCID Icon,
Wim van SchootenTeneobio, Inc., Menlo Park, CA, USAView further author information
,
Roland BuelowTeneobio, Inc., Menlo Park, CA, USAView further author information
&
Shelley Force AldredTeneobio, Inc., Menlo Park, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2095-7646View further author information
ORCID Icon show all
Pages 639-652 | Received 29 Oct 2018, Accepted 21 Jan 2019, Published online: 20 Feb 2019

Citations (59)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Han Ping Loh, Farouq Bin Mahfut, Serene W Chen, Yuhan Huang, Jianxin Huo, Wei Zhang, Kong Peng Lam, Shengli Xu & Yuansheng Yang. (2023) Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies. mAbs 15:1.
Read now
Kathryn Ball, Simon J Dovedi, Pavan Vajjah & Alex Phipps. (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 15:1.
Read now
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein & Katherine E. Harris. (2022) A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer. OncoImmunology 11:1.
Read now
Gabrielle Leclercq, Nathalie Steinhoff, Hélène Haegel, Donata De Marco, Marina Bacac & Christian Klein. (2022) Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. OncoImmunology 11:1.
Read now
Meixiao Long, Alice S. Mims & Zihai Li. (2022) Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations 51:8, pages 2176-2214.
Read now
Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang & Javier Chaparro-Riggers. (2022) Bispecific antibodies for immune cell retargeting against cancer. Expert Opinion on Biological Therapy 22:8, pages 965-982.
Read now
Edmund Watson, Faouzi Djebbari, Alexandros Rampotas & Karthik Ramasamy. (2022) BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. Expert Review of Hematology 15:6, pages 503-517.
Read now
Hanley N Abramson. (2021) Immunotherapy of Multiple Myeloma: Promise and Challenges. ImmunoTargets and Therapy 10, pages 343-371.
Read now
Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau, Benjamin Buelow, Kevin Dang, Laura M. Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim Van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein & Udaya S. Rangaswamy. (2021) TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. mAbs 13:1.
Read now
Wei Chen, Fan Yang, Carole Wang, Jatin Narula, Edward Pascua, Irene Ni, Sheng Ding, Xiaodi Deng, Matthew Ling-Hon Chu, Amber Pham, Xiaoyue Jiang, Kevin C. Lindquist, Patrick J. Doonan, Tom Van Blarcom, Yik Andy Yeung & Javier Chaparro-Riggers. (2021) One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. mAbs 13:1.
Read now

Articles from other publishers (49)

Ian B Robertson, Rachel Mulvaney, Nele Dieckmann, Alessio Vantellini, Martina Canestraro, Francesca Amicarella, Ronan O’Dwyer, David K Cole, Stephen Harper, Omer Dushek & Peter Kirk. (2023) Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clinical and Experimental Immunology.
Crossref
Kim Anh Giang, Thorstein Boxaspen, Yumei Diao, Johan Nilvebrant, Mizuha Kosugi-Kanaya, Minoru Kanaya, Silje Zandstra Krokeide, Fredrik Lehmann, Stefan Svensson Gelius, Karl-Johan Malmberg & Per-Åke Nygren. (2023) Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells. New Biotechnology 77, pages 139-148.
Crossref
Eunhee Lee, Shinai Lee, Sumyeong Park, Yong-Gyu Son, Jiseon Yoo, Youngil Koh, Dong-Yeop Shin, Yangmi Lim & Jonghwa Won. (2023) Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release. Journal for ImmunoTherapy of Cancer 11:10, pages e007494.
Crossref
Yen Hoon Luah, Tongjin Wu & Lih Feng Cheow. (2023) Identification, sorting and profiling of functional killer cells via the capture of fluorescent target-cell lysate. Nature Biomedical Engineering.
Crossref
Zahra Bahrami Dizicheh, I-Ling Chen & Patrick Koenig. (2023) VHH CDR-H3 conformation is determined by VH germline usage. Communications Biology 6:1.
Crossref
Sungwook Jung, Moufida Ben Nasr, Baharak Bahmani, Vera Usuelli, Jing Zhao, Gianmarco Sabiu, Andy Joe Seelam, Said Movahedi Naini, Hari Baskar Balasubramanian, Youngrong Park, Xiaofei Li, Salma Ayman Khalefa, Vivek Kasinath, MacKenzie D. Williams, Ousama Rachid, Yousef Haik, George C. Tsokos, Clive H. Wasserfall, Mark A. Atkinson, Jonathan S. Bromberg, Wei Tao, Paolo Fiorina & Reza Abdi. (2023) Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes. Advanced Materials.
Crossref
David Flowers, David Bassen, Georgi I. Kapitanov, Diana Marcantonio, John M. Burke, Joshua F. Apgar, Alison Betts & Fei Hua. (2023) A next generation mathematical model for the in vitro to clinical translation of T-cell engagers. Journal of Pharmacokinetics and Pharmacodynamics 50:3, pages 215-227.
Crossref
Dinghe Wang, Lige Zhang, Baoli Wang, Le Zhao, Lan Deng, Wei Xu & Haomin Huang. (2023) Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines. Protein Expression and Purification 205, pages 106242.
Crossref
Latifa Zekri, Martina Lutz, Nisha Prakash, Timo Manz, Boris Klimovich, Stefanie Mueller, Sebastian Hoerner, Ilona Hagelstein, Monika Engel, Anna Chashchina, Martin Pfluegler, Jonas S. Heitmann, Gundram Jung & Helmut R. Salih. (2023) An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Molecular Therapy 31:4, pages 1033-1045.
Crossref
Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis & Thomas Pabst. (2022) Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells 11:17, pages 2747.
Crossref
Madelyn Espinosa-Cotton & Nai-Kong V. Cheung. (2022) Bispecific antibodies for the treatment of neuroblastoma. Pharmacology & Therapeutics 237, pages 108241.
Crossref
Hantao Lou & Xuetao Cao. (2022) Antibody variable region engineering for improving cancer immunotherapy. Cancer Communications 42:9, pages 804-827.
Crossref
Edmund Watson, Sarah Gooding & Karthik Ramasamy. (2022) Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. The Hematologist 19:3.
Crossref
Tara ArvedsonJulie M. BailisCarolyn D. Britten, Matthias Klinger, Dirk Nagorsen, Angela Coxon, Jackson G. EgenFlavius Martin. (2022) Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annual Review of Cancer Biology 6:1, pages 17-34.
Crossref
Julie A. Zorn, Matthew L. Wheeler, Ralston M. Barnes, Jim Kaberna, Winse Morishige, Marek Harris, Richard Y.-C. Huang, Jack Lohre, Yu Ching Chang, Bryant Chau, Kathleen Powers, Ian Schindler, Naveen Neradugomma, Winston Thomas, Xiaoyun Liao, Yinhan Zhou, Sean M. West, Feng Wang, Srikanth Kotapati, Guodong Chen, Sayumi Yamazoe, Anastasia Kosenko, Gavin Dollinger, Tim Sproul, Arvind Rajpal & Pavel Strop. (2022) Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. Scientific Reports 12:1.
Crossref
Dain Moon, Nara Tae, Yunji Park, Seung-Woo Lee & Dae Hee Kim. (2022) Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Network 22:1.
Crossref
John S. Schardt, Harkamal S. Jhajj, Ryen L. O'Meara, Timon S. Lwo, Matthew D. Smith & Peter M. Tessier. (2022) Agonist antibody discovery: Experimental, computational, and rational engineering approaches. Drug Discovery Today 27:1, pages 31-48.
Crossref
Patty A. Culp, Jeremiah D. Degenhardt, Danielle E. Dettling & Chad May. 2022. Cancer Immunology and Immunotherapy. Cancer Immunology and Immunotherapy 267 319 .
Pamela D. Garzone & Yow-Ming C. Wang. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology 611 651 .
Daisuke Kamakura, Ryutaro Asano & Masahiro Yasunaga. (2021) T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals 14:11, pages 1172.
Crossref
Nadine Aschmoneit, Lennart Kühl, Oliver Seifert & Roland E Kontermann. (2021) Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. Journal for ImmunoTherapy of Cancer 9:11, pages e003616.
Crossref
Zhijian Duan & Mitchell Ho. (2021) Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodies. Antibody Therapeutics 4:4, pages 208-211.
Crossref
Mashhour Hosny, Christie P. M. Verkleij, Jort van der Schans, Kristine A. Frerichs, Tuna Mutis, Sonja Zweegman & Niels W. C. J. van de Donk. (2021) Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. Journal of Clinical Medicine 10:19, pages 4593.
Crossref
Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister & Maria Theresa Krauth. (2021) The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers 13:18, pages 4701.
Crossref
Shuhang Wang, Kun Chen, Qi Lei, Peiwen Ma, Andy Qingan Yuan, Yong Zhao, Youwei Jiang, Hong Fang, Shujun Xing, Yuan Fang, Ning Jiang, Huilei Miao, Minghui Zhang, Shujun Sun, Zicheng Yu, Wei Tao, Qi Zhu, Yingjie Nie & Ning Li. (2021) The state of the art of bispecific antibodies for treating human malignancies. EMBO Molecular Medicine 13:9.
Crossref
Brian Belmontes, Deepali V. Sawant, Wendy Zhong, Hong Tan, Anupurna Kaul, Famke Aeffner, Sarah A. O’BrienMatthew ChunRajkumar Noubade, Jason EngHayley MaMarkus MuenzPeng Li, Benjamin M. AlbaMelissa Thomas, Kevin Cook, Xiaoting Wang, Jason DeVoss, Jackson G. Egen & Olivier Nolan-Stevaux. (2021) Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors. Science Translational Medicine 13:608.
Crossref
Alison Crawford & Danica Chiu. (2021) Targeting Solid Tumors Using CD3 Bispecific Antibodies. Molecular Cancer Therapeutics 20:8, pages 1350-1358.
Crossref
Nadine Aschmoneit, Sophia Steinlein, Lennart Kühl, Oliver Seifert & Roland E. Kontermann. (2021) A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Scientific Reports 11:1.
Crossref
Mathilde Poussin, Arlene Sereno, Xiufeng Wu, Flora Huang, Jason Manro, Shanshan Cao, Carmine Carpenito, Andrew Glasebrook, Daniel J Powell Jr & Stephen J Demarest. (2021) Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. Journal for ImmunoTherapy of Cancer 9:7, pages e002444.
Crossref
Hanley N. Abramson. 2021. Monoclonal Antibodies. Monoclonal Antibodies.
Kinan Alhallak, Jennifer Sun, Amanda Jeske, Chaelee Park, Jessica Yavner, Hannah Bash, Berit Lubben, Ola Adebayo, Ayah Khaskiah & Abdel Kareem Azab. (2021) Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers 13:12, pages 2853.
Crossref
Kevin Dang, Giulia Castello, Starlynn C Clarke, Yuping Li, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Rong Deng, Serena Kwek, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Lawrence Fong & Pranjali Dalvi. (2021) Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. Journal for ImmunoTherapy of Cancer 9:6, pages e002488.
Crossref
Ulrich BrinkmannRoland E. Kontermann. (2021) Bispecific antibodies. Science 372:6545, pages 916-917.
Crossref
Xiaotian Zhong & Aaron M. D’Antona. (2021) Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies 10:2, pages 13.
Crossref
Ajit Singh, Sundee Dees & Iqbal S. Grewal. (2021) Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer 124:6, pages 1037-1048.
Crossref
David J. DiLillo, Kara Olson, Katja Mohrs, Thomas Craig Meagher, Kevin Bray, Olga Sineshchekova, Thomas Startz, Jessica Kuhnert, Marc W. Retter, Stephen Godin, Prachi Sharma, Frank Delfino, John Lin, Eric Smith, Gavin Thurston & Jessica R. Kirshner. (2021) A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Advances 5:5, pages 1291-1304.
Crossref
Kasandra Bélanger & Jamshid Tanha. (2021) High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources. Protein Engineering, Design and Selection 34.
Crossref
Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman & Thorbald van Hall. (2021) Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers 13:2, pages 287.
Crossref
Vladimir Voynov, Paul J. Adam, Andrew E. Nixon & Justin M. Scheer. (2020) Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. Antibodies 9:4, pages 65.
Crossref
Alison Betts & Piet H. van der Graaf. (2020) Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology. Clinical Pharmacology & Therapeutics 108:3, pages 528-541.
Crossref
Hanley N. Abramson. (2020) B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. International Journal of Molecular Sciences 21:15, pages 5192.
Crossref
Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin & Jo Caers. (2020) Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology 11.
Crossref
Omid Vafa & Nathan D. Trinklein. (2020) Perspective: Designing T-Cell Engagers With Better Therapeutic Windows. Frontiers in Oncology 10.
Crossref
Brian H. Santich, Jeong A. Park, Hoa TranHong-Fen GuoMorgan Huse & Nai-Kong V. Cheung. (2020) Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Science Translational Medicine 12:534.
Crossref
Aerin Yoon, Shinai Lee, Sua Lee, Sojung Lim, Yong-Yea Park, Eunjung Song, Dong-Sik Kim, Kisu Kim & Yangmi Lim. (2020) A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors. Biomolecules 10:3, pages 399.
Crossref
Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu & Jijie Gu. (2020) Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics 3:1, pages 18-62.
Crossref
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Hong Li, You Li, Cheng Wang, Shouye Wang & Mitchell Ho. (2019) Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic. Antibody Therapeutics 2:4, pages 79-87.
Crossref
Strohl & Naso. (2019) Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies 8:3, pages 41.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.